ASH 2022 | Outcomes of patients with AML treated with low-intensity re-induction therapy for persistent disease
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, describes the findings of a study that compared the safety profile and survival outcomes of patients treated with low-intensity re-induction therapy for persistent disease after a single intensive induction cycle for newly diagnosed acute myeloid leukemia (AML). Overall, it was found that low-intensity re-induction therapy resulted in shorter hospital stays and a lower transfusion burden, with similar remission and long-term survival rates compared to patients treated with intensive induction chemotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Actinium Pharmaceuticals: Research Funding; Pfizer: Research Funding; Helsinn Healthcare: Research Funding; AltruBio Inc.: Research Funding; Stemline: Honoraria; Amgen: Honoraria; Incyte: Research Funding; AbbVie: Honoraria; Daichi Sankyo: Honoraria; Servier: Honoraria.
